COVID-19：イベルメクチンの鼻腔用スプレー登場（動画）：
Finnish Biotech Secures U.S. Patent for Ivermectin-based Nasal Spray：
COVID-19：伊维菌素鼻喷剂出现：Therapeutica Borealis
ー低中所得国 (LMIC) で COVID-19 に立ち向かうー
Therapeutica Borealis：
フィンランドのトゥルクに拠点を置くバイオテクノロジーベンチャー
米国特許商標庁 (USPTO) から COVID-19 治療の特許を取得しました。
「イベルメクチンと他のいくつかの注目すべき治療法」に基づいています。
ヒドロキシクロロキンとアプロチニン：
「ウイルスの体内侵入・複製を阻止する点鼻スプレー」として開発されました。
この特定の治験薬：
低コストで大量生産でき、「ワクチン予防接種が普及していない世界中の地域」に配布できます。
Now the company
seeks pharmaceutical company partners to scale up research and go-to-market.This new venture known as Therapeutica Borealis
is affiliated with the University of Turku and is located in Turku, Finland, in the far southwest.
This city of only about 200,000
represents the nation’s top life sciences cluster, which is actually the source of nearly 70% of Finish biopharma exports.
The city has a concentration of over 1,000 researchers distributed over more than 100 research groups making up what’s known as “Health Turku.”
This particular investigational nasal therapeutic product
involves active substances, including aprotinin,
hydroxychloroquine,
and ivermectin,used in this particular configuration in a targeted manner on the mucous membrane of the upper respiratory tract.
The founders declare that
this targeted use actually allows for lower dosage of the active substances, making the treatment safe and more concentrated for efficacy.